United States Patent 10,632,199: Scope, Claim Map, and US Patent Landscape for a Bupivacaine–Meloxicam Sustained-Release Co-Composition
Executive summary: US Patent 10,632,199 claims a “consisting essentially of” analgesic composition made of (i) bupivacaine and (ii) meloxicam at tightly constrained weight percentages and bupivacaine:meloxicam ratios, delivered via a sustained-release vehicle, with dependent coverage focused on a bioerodible polymer (polyorthoester) and specific solvent plus triglyceride (triacetin) viscosity reducing agent systems. The independent composition claim is broad on delivery-vehicle type (but limited to sustained-release and “no additional active agents” in claim 1), while the strongest patent “lock” is the dependent polyorthoester sub-structure and the specific formulation envelope (polyorthoester + DMSO + triacetin, optionally maleic acid). Independent method claims broadly cover administering the claimed composition for analgesia and pain management including prophylaxis, with dependent method claims limited to perineural or surgical wound and postsurgical pain use.
What patents protect bupivacaine plus meloxicam co-formulations in the US (including sustained-release delivery)?
Best reading of the claim set you provided: US 10,632,199 is not a “single-API” formulation patent. It is a combination analgesic delivery patent built around three constraints that drive scope:
- No additional active agents (“consisting essentially of” and “contains no additional active agents” in claim 1).
- Quantitative dosing envelope: meloxicam in 0.005–0.75 wt% and bupivacaine:meloxicam ratio 15:1 to 50:1.
- Delivery system that supports sustained release (explicit in dependent claim 3; functional in claim 1 via “delivery vehicle” and then “wherein the composition is a sustained-release delivery vehicle” in claim 3).
Claim 1: what it covers at the widest US infringement-relevant tier
Claim 1 (independent) recites:
- A composition consisting essentially of:
- delivery vehicle
- bupivacaine
- meloxicam
- Ratio (bupivacaine:meloxicam): about 15:1 to 50:1
- Meloxicam wt%: about 0.005–0.75 wt%
- No additional active agents
Key legal and product-design consequence: In US formulation infringement, claim 1 is broad enough to cover multiple delivery vehicle families if they meet sustained-release expectations elsewhere in the claim set (notably via dependent claim 3) and if the formulation contains no other actives. It also leaves room for solvent and excipient variability because excipients are not “additional active agents.”
Dependent composition claims: where scope narrows sharply
- Claim 2: bupivacaine 0.1–8.0 wt%, meloxicam 0.01–0.5 wt% (tightens both endpoints).
- Claim 3: delivery vehicle is sustained-release.
- Claim 4: delivery vehicle is aqueous based (further narrow).
- Claim 5: sustained-release vehicle is bioerodible or biodegradable polymer.
- Claim 6: the polymer is a polyorthoester with a defined structural representation (this is where design-arounds become chemistry-specific).
- Claims 7–12: polyorthoester formulation plus a polar aprotic solvent (DMSO, N-methylpyrrolidone, or dimethylacetamide) and a triglyceride viscosity reducing agent (triacetin in claim 11 envelope), and optionally maleic acid.
What is the exact scope of US patent 10,632,199 claims 1–20 (by dosage, ratio, and delivery vehicle)?
Composition scope (claims 1–16)
Below is the scope ladder from broadest to narrowest.
Claim 1: core combination + ratio + meloxicam wt% + no other actives
- Delivery vehicle
- Bupivacaine + meloxicam
- Bupivacaine:meloxicam ratio: 15:1 to 50:1
- Meloxicam amount: 0.005–0.75 wt%
- No additional active agents
Claim 2: numeric endpoint refinement
- Bupivacaine: 0.1–8.0 wt%
- Meloxicam: 0.01–0.5 wt%
Claim 3–4: delivery form constraints
- Claim 3: sustained-release delivery vehicle
- Claim 4: aqueous based
Claim 5–6: polymer identity and structure
- Claim 5: bioerodible or biodegradable polymer
- Claim 6: polyorthoester with Formula I where:
- R* is C1–4 alkyl
- n is 5–400
- A is a diol, with A defined as R1 and/or R3
- Fraction of A units that are formula R1: 0–25 mol%
- Specific definition language for R3 and R1 and the subunit composition
- The resulting component is “the subunit” per the formula recitation
This claim 6 is the most “chemical-structure-gated” part of the estate you provided.
Claims 7–8: solvent selection + polymer system
- Claim 7: delivery vehicle comprises
- polyorthoester
- polar aprotic solvent
- triglyceride viscosity reducing agent
- Claim 8: polar aprotic solvent is one of:
- dimethyl sulfoxide (DMSO)
- N-methyl pyrrolidone
- dimethyl acetamide
Claims 9–10: revised numeric endpoints
- Claim 9: bupivacaine 0.01–7.5 wt%
- Claim 10: meloxicam 0.005–0.25 wt%
Claim 11: full quantitative formulation envelope
- Delivery vehicle comprises:
- 40–75 wt% polyorthoester
- 5–12 wt% DMSO
- 20–40 wt% triacetin
- Bupivacaine: 1–5 wt%
Claim 12: optional acid additive
- Delivery vehicle further comprises:
Claims 13–14: meloxicam sub-ranges
- Claim 13: meloxicam 0.005–0.25 wt%
- Claim 14: meloxicam 0.005–0.125 wt%
Claims 15–16: tighter ratio sub-ranges
- Claim 15: bupivacaine:meloxicam 20:1–40:1
- Claim 16: bupivacaine:meloxicam 30:1–35:1
Method scope (claims 17–20)
- Claim 17 (independent method): method for producing analgesia or pain relief by administering the claim 1 composition to a subject.
- Claim 18 (independent method): managing pain or prophylactic treatment of pain by administering the claim 1 composition.
- Claim 19: administration perineural or to a surgical wound.
- Claim 20: pain is postsurgical pain.
Infringement relevance: Method claims are easiest to assert when a product label, IFU, clinical trial protocol, or reimbursement documentation specifies timing, pain condition, or anatomic target matching claims 19–20.
Which limitations in claim 1 create the main infringement “sweep,” and which create the main design-around pressure?
Sweep drivers (hard to avoid without changing the product)
- Combination requirement: both bupivacaine and meloxicam must be present.
- Ratio and meloxicam wt%: the accused product must land inside the ratio and meloxicam concentration bands of claim 1 (and likely also claim 2, if a defendant tries to litigate using the narrower dependent claims).
- No additional active agents: avoids easy “replace with different NSAID” or “add another active” approaches.
Design-around levers (high probability for competitive differentiation)
- Move outside bupivacaine:meloxicam ratio 15:1–50:1 and/or outside meloxicam 0.005–0.75 wt%.
- Add another “active agent” would likely break the “no additional active agents” element, but it changes the product entirely.
- If the product is sustained-release but not matching claim 3, claim 1 may still be argued under doctrine-of-claim-consistency depending on how “delivery vehicle” is construed; practically, most sustained-release platforms will be pleaded under claim 3 at least.
- The strongest design-around is to avoid the polyorthoester structural definition in claim 6 or to avoid the specified solvent/polymer/triglyceride arrangement in claim 7–12, particularly the quantified envelope in claim 11.
How does US 10,632,199 compare with typical US analgesic combination patent estates (bupivacaine + NSAID)?
Typical US landscape pattern for local analgesic combinations
Combination analgesic IP usually clusters into:
- API identity and fixed-dose combinations (often broad but dependent on numeric ranges).
- Delivery system patents (matrix, polymer, solvent, viscosity agents).
- Method-of-use (anatomic route and pain state: postsurgical, perineural, wound site).
In this estate, the center of gravity is the formulation:
- Claim 1 captures the combination within quantitative boundaries.
- The dependent chain builds a specific sustained-release delivery vehicle, with the most concrete chemistry in claim 6 and the most concrete manufacturing composition in claim 11 (polyorthoester + DMSO + triacetin).
What patent expiration and exclusivity timelines control freedom to operate for US 10,632,199?
Cannot be completed from the claim text alone. Expiration requires filing date, priority chain, and any PTA/terminal disclaimers. The prompt provides only claims, not bibliographic data needed to calculate US patent term.
What formulations are protected by US 10,632,199 (and what numeric “infringement corridors” do they define)?
Protected corridor #1: broad combination claim 1
- bupivacaine:meloxicam = 15:1 to 50:1
- meloxicam wt% = 0.005 to 0.75
Protected corridor #2: formulation tightening by claim 2 and claim 10
- bupivacaine wt% 0.1–8.0 (claim 2) and 0.01–7.5 (claim 9)
- meloxicam wt% 0.01–0.5 (claim 2) and 0.005–0.25 (claim 10)
Protected corridor #3: vehicle-anchored envelope
- sustained release (claim 3)
- aqueous based (claim 4)
- bioerodible polymer (claim 5)
- polyorthoester structure (claim 6)
- polar aprotic solvent choice limited (claim 8)
- triacetin as triglyceride viscosity reducing agent
- quantified vehicle envelope in claim 11:
- polyorthoester 40–75 wt%
- DMSO 5–12 wt%
- triacetin 20–40 wt%
- bupivacaine 1–5 wt%
- optional maleic acid 0.01–0.3 wt% (claim 12)
What generic entry risks exist for a bupivacaine plus meloxicam sustained-release product?
Entry risk logic under claim structure (not tied to Orange Book listings because those are not provided):
- A generic that matches claim 1’s ratio and meloxicam wt% while using a sustained-release delivery vehicle risks literal infringement.
- Even if numeric endpoints are adjusted, the dependent claims can catch alternative product versions if they still land within the narrower bands (claims 2, 9, 10, 11, 13–14, 15–16).
- A competitor that uses a different polymer than polyorthoester, or a different solvent system, may try to avoid claims 6–12, but still needs to avoid claim 1’s broad combination core.
What patent litigation affects US 10,632,199 and what Paragraph IV / Hatch-Waxman pathways are relevant?
Cannot be determined from the provided material. Litigation posture, settlements, and any ANDA filings require case dockets, Orange Book entries, and procedural history not included in the prompt.
How strong is the patent estate for the bupivacaine–meloxicam sustained-release concept (based on claim construction indicators)?
Strength signals present in the claims you provided
- Clear numeric ranges (ratio and wt%) in claim 1 plus multiple nested dependent sub-ranges.
- Structure-specific polymer identity in claim 6, which can provide strong validity and enforceability leverage against “similar-but-not-the-same” polymer substitutions.
- Specific formulation quantitative envelope in claim 11, which can reduce design ambiguity in infringement.
- Multiple method routes/states in claims 19–20 (perineural/surgical wound; postsurgical pain).
Weakness signals that defendants typically attack (structural)
- Claim 1’s “consisting essentially of” leaves room for excipient and may allow arguments around what constitutes an “additional active agent.”
- Claim 6’s long formula recitation can invite claim construction fights about coverage of variations. Still, structural definitions often remain enforceable when the competitor’s chemistry matches the subunit boundaries.
Key Takeaways
- US 10,632,199 centers on a bupivacaine + meloxicam sustained-release composition bounded by ratio (15:1–50:1) and meloxicam wt% (0.005–0.75), with no additional active agents.
- The claim set escalates into a polyorthoester-based bioerodible sustained-release system (claim 6) with a defined solvent/triglyceride system and a quantified polyorthoester + DMSO + triacetin envelope (claim 11).
- Method claims cover analgesia and prophylaxis, with route and pain-state limits at perineural/surgical wound and postsurgical pain (claims 19–20).
- The most actionable design-arounds are to miss the ratio/wt% bands of claim 1 or to avoid the polyorthoester structural definition plus the specific formulation envelope in claims 6–12.
FAQs
1) What ratio of bupivacaine to meloxicam is required for infringement of claim 1?
About 15:1 to 50:1.
2) What is the claimed meloxicam weight-percentage range in claim 1?
About 0.005–0.75 wt%.
3) Does US 10,632,199 require sustained release?
Claim 1 includes a “delivery vehicle,” while claim 3 expressly requires a sustained-release delivery vehicle; the strongest enforceable formulation set is tied to the dependent sustained-release chain.
4) Which solvents are explicitly allowed in the claimed delivery vehicle?
DMSO, N-methylpyrrolidone, or dimethylacetamide (claim 8).
5) What is the quantified triacetin formulation envelope in claim 11?
Triacetin is 20–40 wt%, with polyorthoester at 40–75 wt% and DMSO at 5–12 wt%.
References
- United States Patent 10,632,199 (claims provided in prompt).
